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THE ADVENT of novel immunosuppressive agents has 
made successful transplantation of organ allografts a 
clinical reality. However, chronic use of these nonspecific 
drugs is associated with unwanted side effects; necessitating 
the evolution of strategies that would allow for the induc-
tion of donor-specific tolerance, enhancing allograft sur-
vival and ultimately leading to reduction or withdrawal of 
immunosuppression (IS). Having speculated that persis-
tence of donor cell chimerism may play an important role in 
the, acceptance of whole organ allografts,I-3 we initiated a 
prospective trial in December 1992 to enhance this phe-
nomenon by adjuvant infusion of unmodified bone marrow 
(BM) into 85 recipients of primary whole organ allografts. 
Failure to obtain permission to harvest vertebral bodies 
from the cadaveric donors resulted in accrual of 54 recipi-
ents of organ alone, which were followed as contempora-
neous controls. Reported herein is the outcome of these 
patients at their latest follow-up. 
MATERIALS AND METHODS 
Patients 
Between December 1992 and December 1994. 85 patients were 
simultaneously transplanted with ABO-compatible unmodified do-
nor BM and liver (II = 34). kidney (n = 36). heart (n = 10), or lung 
(n = 5). The mean follow-up was 360:: 179 (range, 90 to 852 days). 
The mean recipient age was 46 :: 11.3 years. and the mean donor 
age was 32.7 :: 16.2 years. Additionally. there were 54 recipients of 
liver (n = 29). kidney (n = 20). heart (1/ = 4). or lung (1/ = I) 
allografts alonc nn whom consent to harvest vertebral bodies from 
the cadaveric donors was not available were monitored as con-
trols). Their follow-up ranges from 130 to 535 days (405 :: 107 
days). Isolated pancreatic islets wen: infused into one lil'er and six 
kidney rccipients who also received adjuvant BM. Seven 8M-
augmented and three nonaugmcnted kidney recipients also re-
ct:ived a concomitant pancreas transplant. 
Bone Marrow and Pancreatic Islets Cell Isolation 
1,\1 cells werc isobted from the wrtcbral bodies of the cadaveric 
dOllllrs by a method d~scribed previousl\': Following organ rc\as-
cularization. :; to .'i )( 10' unmodified cells.kg body weight were 
infused via a central IV line into the recipients. Iskts from the 
panen:ata of the B\1'organ donor were isolateu by a modification 
of the autllmated methlld.' and subsequently infused into the 
portal vein ()f the allu~raft recipients shortly after fI.'vascularization. 
Immunosuppression 
All patients rel'cl\cd tacrolimus along with ,kroids and did not 
undn~ll ;iI1Y evwablative or cytllreductlve conditioning priLlr to 
organ transpLlIllation. All epislldes of rejectinn or graft-versus-host 
dl,case (Ci VII D) were treated with min()r moditicatiuns in doses of 
routine IS. In the event a steroid-resistant rejection was encoun-
tered, it was treated with a short course of OKTI or ATG. 
In Vitro Studies 
Pretransplant and serially posttransplant (every other month) in 
vitro studies were performed using the PBMCs of the recipients to 
detect chimerism (by flow cytometry and PCR) and to determine 
their immune status (by MLR, LOA, recall antigens, ConA, and 
PHA). These methods have been detailed elsewhere.' 
RESULTS AND DISCUSSION 
No complications of BM infusion were witnessed in any of 
the 85 primary organ allograft recipients, and their conva-
lescence was rapid. All but four (5%) BM-augmented 
recipients are alive whereas, 7 of 54 (13%) control patients 
died during this follow-up (Table 1). None of the deaths in 
the augmented group were related to BM infusion. The two 
BM-augmented liver patients succumbed to fulminant sep-
ticemia 3 and 5 weeks posttransplantation_ Two additional 
heart and BM recipients died with functioning grafts on 
postoperative days 24 and 267 due to septicemia and 
pulmonary thrombo-embolism, respectively. Two kidney 
allografts in the BM-augmented group were lost 16 months 
posttransplantation (noncompliance in one and rejection in 
the other). Polyoma virus infection and rejection was the 
cause for loss of another kidney approximately 375 days 
posttransplantation. The tempo, severity, and incidence of 
rejection were comparable in the patients in the study and 
control group. Only two (2.3%), both BM-augmented liver 
recipients, developed asymptomatic GVHD. Limited to the 
skin, it resolved spontaneously in one. whereas a slight 
increase in routine steroid dose was required for its invo-
lution in the other.4 The most recent blood sample obtained 
from evaluable patients showed a significantly higher inci-
dence (69 of 79.87%) of multilineage donor cell chimerism 
in the 8M-augmented as compared to that in the control 
(23 to 43, RP~DcF group (Table 1). Additionally. 52':, of the 
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Table 1. Current Graft Function, Survival, and Donor Cell Chimerism in BM-Augmented 
and Nonaugmented Whole Organ Allograft Recipients 
Graft survival 
Transplant groups n n (%) 
Livers: 
8M-Augmented 34 32/34 (94%) 
Nonaugmented 29 25/29 (86%) 
Kidney: 
8M-Augmented 36 33/36 (92%) 
Nonaugmented 20 17/20 (85%) 
Hearts: 
8M-Augmented 10 8/10 (80%) 
Nonaugmented 04 4/04 (100%) 
Lungs: 
8M-Augmented 05 5/05 (100%) 
Nonaugmented 01 0 (0%) 
'In evaluable patients at the last sample tested. 
8M-augmented liver recipients had evidence of donor-
specific hyporeactivity as compared to 26% of the controls. 
It is noteworthy that in the recipients of other organs. 
immune modulation was analogous in both the control and 
the study group at the last sample tested. 
In summary, adjuvant 8M infusion into whole organ 
allograft recipients was safe and associated with augmenta-
tion of chimerism. Although its eventual effect remains 
speCUlative, it could be argued that its presence may have 
salutary effects on graft and patient survival and may also 
reduce the risk of chronic rejection.6 
Graft function (y - SD! Positive for donor cells' 
T. Bill (mgldL) Creatinine (mg/dL! n (%) 
0.6:': 2 30/31 (97%) 
0.7:,: 3 13/25 (52%) 
1.9 :': 1.2 30131 (97%) 
2.1 :!: 1.3 09114 (64%) 
Good graft function 5/8 (63%) 
Good graft function 3/4 (25%) 
Good graft function 4/5 (80%) 
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